References
- Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med 2006;19:310–6.
- Roche pharmaceuticals (2007) Package insert. Xeloda (capecitabine). MoH approved leaflets July 2007.
- Jones KL, Valero V. Capecitabine-induced pancreatitis. Pharmacotherapy 2003;23:1076–8.
- Sela GB, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: Case report and review of the literature. Cancer Chemother pharmacol 2009;63:779–82.
- Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced hypertriglyceridemia: A report of two cases. Anticancer Res 2006;26:2249–52.
- Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 2006;40:328–31.
- Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (xeloda) as monotherapy in advanced breast and colorectal cancer: Effectiveness and side-effects. Anticancer Res 2007;27:1653–6.
- Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE. . Influence of 5-fluorouracil on serum lipids. Acta Oncol 1995;34:253–6.